CION Ameerpet
A quote for one infusion tells you almost nothing. Anti-angiogenic maintenance — the class most families know by its first brand name — is dosed by body weight, given every three weeks, and continued for months, so the only number worth having is the whole-course number. This page shows you exactly how it is built up, and what to ask before you agree to any of it.
Type bevacizumab cost india into a search box and you get figures ranging from a few thousand rupees to well over a lakh, every one of them presented as though it were the answer. They are answers to different questions. Some quote a single vial. Some quote one infusion. Some quote the originator brand and some an Indian biosimilar, and almost none of them include the day-care charge, the monitoring, or the plain fact that this treatment runs for months rather than weeks.
This is a maintenance-class treatment. It is given as an intravenous infusion, usually every three weeks alongside platinum-based chemotherapy, and then continued on its own after the chemotherapy course ends. How the class actually works, who benefits from it and what it asks of you is covered in our guide to anti-angiogenic therapy for ovarian cancer. This page is only about the money.
Four things decide your number, and you can establish all four in one conversation: the dose your team plans, how many cycles they plan, whether the originator brand or an Indian biosimilar is supplied, and what is charged on top for the day-care visit and the monitoring. Ask for all four together and the estimate stops being a guess. Women searching avastin cost india are usually looking for exactly this, and finding a vial price instead.
It is worked out per kilogram, so two women on an identical schedule can have genuinely different drug bills. That is not negotiable — but it does mean a figure quoted to someone else tells you very little about your own.
The large first-line trials used doses that differ two-fold, and both are in everyday use. Ask which one is planned for you. It is the single biggest lever on the total, and most people never think to ask.
Several Indian-manufactured biosimilar versions of this molecule are approved and widely used, and they cost substantially less than the originator brand. Your oncologist should tell you which one a quote refers to.
The per-cycle figure is what appears on the estimate. The course figure is what your family has to plan around. Multiply it out before the first infusion, not after the third.
The two trials that established anti-angiogenic maintenance in first-line ovarian cancer used different doses of the same drug. GOG-218 used 15 mg/kg every three weeks and continued maintenance to about 15 months; ICON7 used half that dose, 7.5 mg/kg, for about 12 months. Both delayed progression, and neither showed an overall survival benefit for the trial population as a whole. Because this class is dosed by body weight, the dose level your team chooses can change the drug bill for an entire course by roughly a factor of two — which is why “what does it cost?” has no answer until you know the dose, the number of cycles and the product. Source: Burger RA et al., New England Journal of Medicine (2011); Perren TJ et al., New England Journal of Medicine (2011); NCCN Ovarian Cancer guidelines.
These are the indicative ranges CION already publishes for ovarian cancer treatment in Hyderabad. Treat them as the starting point of a conversation, not as a quotation — your own figure comes from your dose, your cycle count and the product supplied.
| What is being charged | Indicative range (INR) | What moves it |
|---|---|---|
| Anti-angiogenic (anti-VEGF) infusion — per cycle | ₹60,000 – ₹1,50,000 | Body weight, the dose level chosen, and whether an Indian biosimilar or the originator brand is supplied. In first-line treatment it is continued for up to about 15 months. |
| Platinum-based chemotherapy — per cycle | ₹25,000 – ₹80,000 | Runs alongside the infusion during the first-line phase, usually six cycles, and finishes well before maintenance does. Costed separately from the infusion. |
| PARP-inhibitor-class maintenance — per month | ₹50,000 – ₹1,20,000 | The other maintenance class: tablets taken at home, chosen on BRCA and HRD status rather than clinical risk. Worth costing side by side before you commit. |
| Day-care visit, nursing and pharmacy handling | Quoted with the drug | Every three weeks for the length of the course. Ask for it as a separate line rather than assuming it is included in the drug price. |
| Monitoring before each dose | Usually part of the visit | Blood pressure and a urine dipstick for protein, every time. Cheap, non-negotiable, and the reason a dose is sometimes held. |
| Response imaging and blood tests | Quoted separately | CT of the abdomen and pelvis at intervals, and CA-125 read as a trend. Neither is included in a drug quote, and both recur over a months-long course. |
*Ranges are indicative and follow the figures already published on our ovarian cancer treatment in Hyderabad page. They are not a quotation and they do not account for insurance or scheme cover. For the wider picture across surgery, chemotherapy and maintenance, see ovarian cancer treatment cost in Hyderabad.
None of these questions is rude, and none of them delays your treatment by more than a conversation. A team that treats them as awkward is telling you something worth knowing.
Not the per-cycle figure. Dose, cycles, product, day-care charge and monitoring — one total, in writing.
The two accepted first-line doses differ two-fold. This moves the drug bill more than anything else you can influence.
Indian biosimilars of this molecule are approved and widely used, and cost substantially less. If the quote is for the originator brand, ask what the alternative would be.
Raised blood pressure or protein in the urine can delay a cycle. Ask whether a drug already purchased is carried forward, and whether the day-care charge still applies.
Scans, blood tests, the chemotherapy running alongside, and any admission if something goes wrong are almost always costed separately.
A months-long expense deserves a plain answer about what it buys in your particular case — including the honest option of not adding it at all.
At CION the expected cost of a full course is put in writing before it begins, including the monitoring. Bring any quote you have already been given — book a free consultation and we will go through it line by line.
Bring your prescription, your CT report and any quote you have already been given. In 45 minutes a medical oncologist can tell you what dose and how many cycles are planned in your case, what the biosimilar option changes, and what the total is expected to be including the monitoring.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If this class would add months of expense without adding much for you, we will say so plainly rather than add it because it is available.
Five questions, one conversation. Ask them before the first infusion rather than after the third, when stopping has become a clinical decision as well as a financial one.
Ask for the dose in mg per kg and the interval — almost always every three weeks. Your weight is part of the calculation, so ask your team to work the arithmetic in front of you rather than quoting a generic per-cycle price. If the plan is the higher of the two accepted dose levels, ask why that one was chosen for you; there is usually a good clinical reason, and you are entitled to hear it.
In first-line treatment this class is generally continued for up to about a year to fifteen months, which is the schedule the trials used. In recurrent disease it is often continued until the cancer progresses or side effects make stopping sensible. Ask for the planned number, and ask what would make it stop earlier — progression, a side effect, or a scan result. That number is what turns a per-cycle price into a real budget.
The originator brand and the Indian biosimilars are not priced alike, and a quote that does not name the product is not a quote. Biosimilars of this molecule have been in routine use in India for years and are supplied by mainstream hospital pharmacies. Ask what is being planned, what the alternative costs, and whether the choice is clinical or commercial.
Cover for maintenance drugs varies by policy and by scheme package, and the only reliable answer comes from your own policy document or the scheme desk — never from a forum. Ask the hospital’s insurance desk to run a cashless pre-authorisation for day-care chemotherapy, and ask specifically whether the drug, the day-care charge and the monitoring are each covered. If you hold Aarogyasri or PMJAY, CGHS, ECHS or ESI entitlement, ask what the relevant package includes and which centres are empanelled.
One document: drug per cycle, number of cycles, day-care and pharmacy charges, monitoring, and the imaging that will be needed along the way. That is the number to take home and discuss with your family. Our overview of ovarian cancer treatment cost in Hyderabad sets it against the rest of the treatment, and the complete guide to ovarian cancer explains where maintenance sits in the whole pathway.
*If the number is not affordable, say so out loud at the start. There are real levers — the dose level, the product supplied, scheme empanelment, and sometimes the honest conclusion that this class would add less for you than it would for someone else. What helps nobody is starting a months-long treatment and stopping it quietly halfway.
Most families arrive here with a piece of paper and a figure on it, and no way of telling whether the figure is reasonable, complete, or even for the right product. That is not a five-minute conversation. Your first consultation at CION is free and runs to about 45 minutes, which is long enough to go through a quote line by line and say what is missing from it.
What usually needs unpicking is specific: whether your risk profile is the kind that benefited in the trials, which dose level is appropriate for you, how this class should be sequenced against PARP-inhibitor-class maintenance so that neither is wasted, and what the whole course is expected to cost including the monitoring. Every case is discussed at a tumour board rather than decided by one doctor alone — including, sometimes, the decision that adding this class is not worth what it would ask of you.
Chemotherapy and maintenance therapy, including anti-angiogenic infusions and the blood pressure and urine checks that go with them, are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Being treated near home matters more than it sounds on a months-long course: every three weeks, travel and a lost day of work are a real part of the cost.
Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed. That is relevant to your budget here, because this class has to be stopped several weeks before an operation and restarted only once the wound has healed — so the timing, and the two bills, have to be planned together rather than discovered in sequence.
Free and unhurried. Long enough to read a quote properly, work out what is missing from it, and say whether this class belongs in your plan at all.
A treatment measured in months deserves a written estimate before it starts — drug, cycles, day-care, monitoring. Decisions for healing, not billing.
Maintenance infusions and the checks that go with them at whichever of our 35+ centres is closest to you, rather than a three-weekly journey into one city hospital.
Medical oncology, imaging and pathology decide maintenance together, including how the two maintenance classes should be sequenced for you.
*This class is not appropriate for everyone with ovarian cancer and is not offered on request. Whether it belongs in your plan depends on your imaging, your surgery, your other conditions and your BRCA and HRD results — book a free consultation to have that assessed properly.
It is quoted per cycle, not per course. The indicative range CION publishes for anti-angiogenic maintenance is ₹60,000 to ₹1,50,000 per cycle, given every three weeks, and in first-line treatment it may be continued for up to about fifteen months. The spread is wide because the dose is calculated from your body weight, because two dose levels are in accepted use and they differ two-fold, and because the originator brand and the Indian biosimilars are not priced alike. Anyone quoting a single national figure is quoting a vial, not a treatment. The useful step is to multiply the per-cycle figure by the number of cycles your team actually plans, add the day-care charge and the monitoring, and ask for that total in writing before the first infusion.
Because the originator carried the cost of the original development programme and held market exclusivity, while biosimilars entered afterwards on a shorter regulatory route that compares the new product with the reference one. Several biosimilar versions of this molecule are approved in India, have been in routine hospital use for years, and cost substantially less than the originator brand. They are not generic copies in the chemical sense; a biosimilar is a large protein manufactured in living cells, and regulators require comparability testing before approval. What this means for you is practical: a quote that does not name the product is incomplete. Ask which one is planned, what the alternative would cost, and whether the choice is being made on clinical grounds or on what the pharmacy happens to stock.
Sometimes, partly, and it depends entirely on your policy and the scheme package rather than on anything a website can promise. Most health insurance policies in India cover day-care chemotherapy, but cover for maintenance drugs specifically varies, and some policies apply sub-limits or exclusions. Ask the hospital insurance desk to run a cashless pre-authorisation and to confirm in writing whether the drug, the day-care charge and the monitoring are each covered. If you hold Aarogyasri or PMJAY, CGHS, ECHS or ESI entitlement, ask which package applies, what it includes, and which centres are empanelled for it, because that determines where treatment has to be delivered. Do this before the first cycle: retrospective claims are far harder than pre-authorised ones.
The honest answer is that this class reliably delays the cancer coming back, and has not been shown to extend overall survival across whole trial populations. In the two large first-line trials, adding it to chemotherapy and continuing it as maintenance pushed progression back by several months without an overall survival gain for the group as a whole, though an exploratory analysis suggested women at higher risk of early progression benefited more. In platinum-resistant recurrence, adding it improved response, delayed progression and improved reported symptoms. Delaying progression is not nothing: it can mean months without treatment, without drainage and without new symptoms. But it is a different claim from living longer, and any team asking you to fund a year of infusions should draw that distinction for you rather than blur it.
Say so at the first consultation rather than partway through, because the levers that exist are most useful before treatment starts. The product supplied can be discussed, since biosimilars cost substantially less than the originator brand. The dose level is a clinical decision but a legitimate question. Scheme empanelment may mean treatment is better delivered at a particular centre. And in some cases the honest conclusion is that this class would add less for you than it would for someone else, in which case not adding it is a proper medical decision rather than a compromise. What helps nobody is beginning a months-long course and stopping it quietly halfway, because the treatment then costs you money without buying the benefit it was meant to.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance therapy, including anti-angiogenic infusions and the blood pressure and urine monitoring that go with them, across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed there, and we say so upfront rather than leave it to be discovered later. Every case is discussed at a tumour board. Because this treatment runs for months, the expected cost of the full course is put in writing before it begins.